James Peyer founds Cambrian Bio to build a pipeline of aging-targeted therapeutics companies

Cambrian Bio

Cambrian BioPharma, led by CEO and co-founder James Peyer, came out of stealth with $60 million to develop medicines against the root causes of aging through a hub-and-spoke model of subsidiary companies. Its affiliate Sensei Biotherapeutics had just gone public, with Cambrian as its largest shareholder, raising $133 million at $600 million valuation.

• $60 million seed funding raised; Cambrian is largest shareholder in affiliated Sensei Biotherapeutics IPO at $600M valuation.
• Hub-and-spoke model: Cambrian combines business, venture capital and incubator functions to develop multiple companies.
• Targets nine hallmarks of aging with 14 novel therapies in development.
• Programs must target aging mechanism AND progress toward FDA approval rapidly while theoretically preventing age-related disease.